NASDAQ$ABOS
Acumen Pharmaceuticals Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Acumen Pharmaceuticals reported financial results for the third quarter of 2021 and provided recent business highlights.
Acumen Pharmaceuticals reported its Q3 2021 financial results, highlighting the closing of its initial public offering in July 2021 with net proceeds of $168.6 million and the enrollment of first patients in INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease. The company's cash and cash equivalents totaled $135.8 million, and marketable securities totaled $94.1 million as of September 30, 2021.
- Closed initial public offering in July 2021, resulting in aggregate net proceeds of $168.6 million.
- Enrolled first patients in INTERCEPT-AD, a Phase 1 clinical trial of ACU193 for early Alzheimer’s disease.
- Cash and cash equivalents totaled $135.8 million and marketable securities totaled $94.1 million as of September 30, 2021.
- Anticipates topline data from the INTERCEPT-AD trial by the end of 2022, subject to the rate of site activation and patient recruitment.
Headline financials
Revenue & EPS history
Acumen · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q3 2021
+0.6%
Avg return
Earnings day
-3.3%
Avg return
5 days after
-6.4%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+35.9%
Q1 2023
Best reaction
-21.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.3% | -9.8% | — | |
| Q1 2026 | -3.5% | -11.7% | -7.8% | |
| Q3 2025 | -1.5% | -19.8% | +8.6% | |
| Q1 2025 | +0.0% | +1.9% | +8.6% | |
| Q4 2024 | +6.0% | -7.3% | -6.9% | |
| Q3 2024 | -21.4% | -25.5% | -35.7% | |
| Q2 2024 | -1.6% | +0.4% | -4.3% | |
| Q1 2024 | +13.1% | +8.6% | -21.4% | |
| Q4 2023 | -3.5% | +8.0% | -20.6% | |
| Q3 2023 | +12.1% | +20.0% | +53.2% | |
| Q2 2023 | -3.1% | +2.0% | -19.9% | |
| Q1 2023 | +35.9% | +15.5% | +0.4% | |
| Q4 2022 | +2.3% | +3.6% | -4.1% | |
| Q3 2022 | -5.1% | -10.6% | -15.3% | |
| Q2 2022 | +4.6% | -11.5% | +9.4% | |
| Q1 2022 | +9.6% | +4.5% | +7.8% | |
| Q4 2021 | -14.8% | -22.0% | -22.2% | |
| Q3 2021 | -17.1% | -23.9% | -46.7% | |
| Q2 2021 | +1.6% | +13.9% | +1.1% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro